Drug intelligence / Profile preview

S-Ethyl N-Phenylisothiourea

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous

Overview

S-Ethyl N-Phenylisothiourea is a chemical compound primarily utilized for research purposes. It functions as a potent inhibitor of all three human isoforms of nitric oxide synthase (NOS): neuronal NOS (nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS). By interfering with the activity of these enzymes, it modulates the production of nitric oxide, a critical signaling molecule involved in various physiological and pathological processes. This compound is not intended for diagnostic or therapeutic use in humans.

Targets

NOS3 (eNOS)

Beyond the preview

Go deeper on S-Ethyl N-Phenylisothiourea.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S-Ethyl N-Phenylisothiourea.

Explore the full profile